Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Brainstorm Cell Therapeutics Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 75 | 57 | −18 |
| Shares | 8.40M | 5.63M | −2.77M (−33.0%) |
| Value | $32.1M | $21.4M | −$10.8M (−33.5%) |
New holders (9)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 371,460 | $1.41M | 0.00% |
| Acadian Asset Management LLC | 139,333 | $529.0K | 0.00% |
| Ergoteles LLC | 124,329 | $472.0K | 0.01% |
| Tibra Equities Europe Ltd | 87,000 | $331.0K | 0.10% |
| HRT Financial LP | 85,997 | $326.0K | 0.00% |
| Renaissance Technologies LLC | 47,600 | $181.0K | 0.00% |
| Jane Street Group, LLC | 12,543 | $48.0K | 0.00% |
| ExodusPoint Capital Management, LP | 12,696 | $48.0K | 0.00% |
| LMR Partners LLP | 11,735 | $45.0K | 0.00% |
Sold out (27)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q1 2021 and filed for Q2 2021 without it.